Clinical trial
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for…
NCT00130728 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00130728 |
|---|---|
| Title | A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer |
| Official title | A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva (Erlotinib) Compared With Tarceva Alone for Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) After Failure of Standard First-Line… |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | bevacizumab, erlotinib HCl, placebo |
| Enrollment | 636 |
| Start date | Jun 8, 2005 |
| Primary completion | Jul 15, 2008 |
| Completion | Dec 23, 2019 |
| First posted | Aug 16, 2005 |
| Last update posted | Jan 14, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: